| Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.200 | GeneticVariation | disease | BEFREE | NUDT15 R139C was strongly associated with the incidence of leukopenia (70.2% mutation vs. 12.8% wild type; P=8.61×10<sup>-19</sup> ; odds ratio, 10.80; 95% CI, 5.89-19.83). | 27604507 | 2016 | ||||
|
0.200 | GeneticVariation | disease | BEFREE | There are 6/69 (8.7%) patients who developed leukopenia and harbored NUDT15 variant, thus showing a strong association for thiopurine-induced toxicity. | 27416873 | 2017 | ||||
|
0.200 | GeneticVariation | disease | BEFREE | Apart from genetic variants in thiopurine S-methyltransferase (TPMT) and nudix hydrolase 15 (NUDT15) genes, polymorphisms in FTO alpha-ketoglutarate dependent dioxygenase (FTO) were found predictive of thiopurine-induced leukopenia, albeit with conflicting results. | 31813937 | 2019 | ||||
|
0.200 | GeneticVariation | disease | GWASCAT | A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. | 25108385 | 2014 | ||||
|
0.200 | GeneticVariation | disease | BEFREE | TPMT and NUDT15 variants predict thiopurine-induced leukopenia. | 31342537 | 2019 | ||||
|
0.200 | GeneticVariation | disease | BEFREE | CYP2D6 rs1135840 and NUDT15 rs116855232 increased the risks of hepatotoxicity and leukopenia with an odds ratio of 2.52 and 4.97, respectively. | 29071720 | 2018 | ||||
|
0.200 | GeneticVariation | disease | BEFREE | NUDT15 rs116855232 variants were strongly associated with a higher cumulative incidence of neutropenia (p < 0.01), and a lower median dose of tolerated MP throughout maintenance treatment (p < 0.01). | 28882023 | 2018 | ||||
|
0.200 | GeneticVariation | disease | BEFREE | NUDT15 R139C was significantly associated with early (<8 weeks) (P = 1.03 × 10(-4)) and late (>8 weeks) leukocytopenia (P = 4.3 × 10(-4)). | 26590936 | 2016 | ||||
|
0.200 | GeneticVariation | disease | GWASCAT | NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study. | 29923122 | 2018 |